Successful treatment of idiopathic anaphylaxis in an adolescent

Pitt, Tracy; Cisneros, Nestor; Kalicinsky, Chrystyna; Becker, Allan B.

doi:10.1016/j.jaci.2010.05.043

Cited by 39 publications

(36 citation statements)

References 5 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Treatment with omalizumab (anti-IgE) continues to be successful in selected patients with otherwise uncontrolled idiopathic anaphylaxis and in those with anaphylaxis during the initiation of specific immunotherapy [40,41].…”

Section: Therapy For Cutaneous and Indolent Systemic Mastocytosismentioning

confidence: 99%

Update on Diagnosis and Treatment of Mastocytosis

Brockow

Ring

2011

Curr Allergy Asthma Rep

View full text Add to dashboard Cite

Mastocytosis is a disorder characterized by increased numbers of mast cells in tissues. Recent clinical observations highlight the association of mastocytosis with an increased risk of anaphylaxis and underline the diversity of this disease. At the molecular level, recent studies have attempted to unravel specific gene expression profiles for activating c-kit mutations in the etiology of mastocytosis. The diagnosis may be facilitated by surrogate markers and detection of aberrant immunophenotypic surface markers. New therapeutic strategies are in development based on intracellular signal pathways, or on application of topical treatments, as are novel forms of cytoreductive therapy, including tyrosine kinase inhibitors.

show abstract

Section: Therapy For Cutaneous and Indolent Systemic Mastocytosismentioning

confidence: 99%

Update on Diagnosis and Treatment of Mastocytosis

Brockow

Ring

2011

Curr Allergy Asthma Rep

View full text Add to dashboard Cite

show abstract

“…Our patient, who had anaphylactic attacks 4-5 times monthly and was diagnosed as having idiopathic anaphylaxis was successfully treated with anti-IgE. Pitt et al (8) showed the effect of omalizumab in a 15-year-old female patient who was diagnosed as having idiopathic anaphylaxis because of systemic mastocytosis. Similar examples are also present for adult patients.…”

Section: Discussionmentioning

confidence: 75%

Omalizumab’s role in the treatment of steroid dependent malignant idiopathic anaphylaxis

2017

View full text Add to dashboard Cite

If an anaphylaxis episode is not caused by an identifiable trigger, it is defined as idiopathic anaphylaxis. Although it is rarely observed, idiopathic anaphylaxis is clinically significant because of its morbidity and fatality risk. No effective treatment has been demonstrated to date. We report a girl aged 16 years who had had malignant idiopathic anaphylaxis since the age of 12 years who was treated successfully with omalizumab. Although she avoided allergic trigger foods such as tomato and seafood, she used to have these attacks twice a week. Attacks were averted by taking 60 mg prednisone. When prednisone was tapered down to 5 mg on every alternate day, the episodes recurred. Later, attacks could not be controlled on <30 mg of prednisone daily. After being steroid-dependent for 4 years, subcutaneous omalizumab 225 mg every two weeks was started. Under omalizumab therapy, the attacks disappeared and prednisone was discontinued. (Turk Pediatri Ars 2017; 52: 105-7)

show abstract

“…In addition to having no episodes of unprovoked anaphylaxis, this patient tolerated three field stings (one bee sting and two unknown Hymenoptera stings), 100 mg bee venom subcutaneously, and controlled bee sting challenge without reaction. Mild decreases in serum tryptase were noted in two cases [21,23], whereas in the case series by Carter et al [19] and case report by Pitt et al [20], overall serum tryptase levels did not change [19,20]. These results suggest that the effect of omalizumab may be mediated through downregulation of FceRI and a concurrent increase in activation threshold of mast cells and not through decreased mast cell numbers.…”

Section: Key Pointsmentioning

confidence: 72%

“…Similarly, in systemic mastocytosis or mast cell activation syndrome (MCAS), abnormal proliferation of mast cells and profound degranulation can lead to recurrent anaphylactic episodes without clear trigger [17,18]. Several case series and reports have described the successful use of omalizumab in patients with systemic mastocytosis or MCAS and recurrent anaphylactic episodes who have failed standard therapy [19][20][21][22][23]. A case report by Kontou-Fili et al [21] reports the successful use of omalizumab in a patient with systemic mastocytosis and unprovoked anaphylaxis, as well as bee-sting provoked anaphylaxis.…”

Section: Key Pointsmentioning

confidence: 99%

Omalizumab and hypersensitivity reactions

Shankar

Petrov

2013

Current Opinion in Allergy &Amp; Clinical Immunology

View full text Add to dashboard Cite

The available studies indicate that omalizumab is effective and well tolerated in decreasing hypersensitivity reactions associated with allergen immunotherapy in patients with allergic rhinitis and mild-to-moderate asthma. Additionally, omalizumab may represent a promising therapy of anaphylaxis with or without known trigger, which should be further investigated with randomized studies. Moreover, additional research is needed to elucidate the mechanism of anaphylaxis with the medication itself.

show abstract

Successful treatment of idiopathic anaphylaxis in an adolescent

Cited by 39 publications

References 5 publications

Update on Diagnosis and Treatment of Mastocytosis

Update on Diagnosis and Treatment of Mastocytosis

Omalizumab’s role in the treatment of steroid dependent malignant idiopathic anaphylaxis

Omalizumab and hypersensitivity reactions

Contact Info

Product

Resources

About